{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:01:50Z","timestamp":1790380910239,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81700119"],"award-info":[{"award-number":["81700119"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the National Natural Science Foundation of Jiangsu Province","award":["BE2018652"],"award-info":[{"award-number":["BE2018652"]}]},{"name":"National Natural Science Foundation of Jiangsu Province","award":["BK20201168"],"award-info":[{"award-number":["BK20201168"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00277-021-04530-y","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T01:14:00Z","timestamp":1620263640000},"page":"697-699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"101","author":[{"given":"Jinyu","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoquan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"issue":"7380","key":"4530_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nature10725","volume":"481","author":"J Zhang","year":"2012","unstructured":"Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen S-C, Wei L, Collins-Underwood JR, Ma J, Roberts KG, Pounds SB, Ulyanov A, Becksfort J, Gupta P, Huether R, Kriwacki RW, Parker M, McGoldrick DJ, Zhao D, Alford D, Espy S, Bobba KC, Song G, Pei D, Cheng C, Roberts S, Barbato MI, Campana D, Coustan-Smith E, Shurtleff SA, Raimondi SC, Kleppe M, Cools J, Shimano KA, Hermiston ML, Doulatov S, Eppert K, Laurenti E, Notta F, Dick JE, Basso G, Hunger SP, Loh ML, Devidas M, Wood B, Winter S, Dunsmore KP, Fulton RS, Fulton LL, Hong X, Harris CC, Dooling DJ, Ochoa K, Johnson KJ, Obenauer JC, Evans WE, Pui C-H, Naeve CW, Ley TJ, Mardis ER, Wilson RK, Downing JR, Mullighan CG (2012) The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481(7380):157\u2013163","journal-title":"Nature"},{"key":"4530_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","volume":"10","author":"E Coustan-Smith","year":"2009","unstructured":"Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, Cheng C, Su X, Rubnitz JE, Basso G, Biondi A, Pui CH, Downing JR, Campana D (2009) Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 10:147\u2013156","journal-title":"Lancet Oncol"},{"issue":"2","key":"4530_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(09)70010-5","volume":"10","author":"JW Taub","year":"2009","unstructured":"Taub JW (2009) Early T-cell precursor acute lymphoblastic leukaemia. Lancet Oncol 10(2):105\u2013106","journal-title":"Lancet Oncol"},{"key":"4530_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/leu.2016.263","volume":"31","author":"A Stengel","year":"2017","unstructured":"Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C (2017) The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia 31:705\u2013711","journal-title":"Leukemia"},{"key":"4530_CR5","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O\u2019Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, D\u00f6hner K, Schlenk RF, D\u00f6hner H, Campbell PJ (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374:2209\u20132221","journal-title":"N Engl J Med"},{"issue":"4","key":"4530_CR6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","volume":"20","author":"G Richard-Carpentier","year":"2020","unstructured":"Richard-Carpentier G, Jabbour E, Short NJ et al (2020) Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 20(4):212\u2013218","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4530_CR7","unstructured":"Farhadfar N, Li Y, May WS et al (2020) Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: a case report and review of literature. Hematol Oncol Stem Cell Ther:S1658\u2013S3876"},{"key":"4530_CR8","doi-asserted-by":"crossref","unstructured":"Puglianini OC, Papadantonakis N (2020) Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts. Ther Adv Hematol 11: doi: 10.1177.","DOI":"10.1177\/2040620720929475"},{"key":"4530_CR9","doi-asserted-by":"crossref","unstructured":"Numan Y, Alfayez M, Maiti A et al. (2018) First report of clinical response to venetoclax in early T-cell precursor acute lymphoblastic leukemia. JCO Precis Oncol, 2: doi: 10.1200.","DOI":"10.1200\/PO.18.00127"},{"key":"4530_CR10","doi-asserted-by":"crossref","unstructured":"La Starza R, Camb\u00f2 B, Pierini A et al. (2019) Venetoclax and bortezomib in relapsed\/ refractory early T-cell precursor acute lymphoblastic leukemia. JCO Precis Oncol, 3. doi: 10.1200.","DOI":"10.1200\/PO.19.00172"},{"issue":"10","key":"4530_CR11","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1002\/ccr3.3041","volume":"8","author":"E Zappone","year":"2020","unstructured":"Zappone E, Cencini E, Defina M et al (2020) Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia. Clin Case Rep 8(10):2000\u20132002","journal-title":"Clin Case Rep"},{"issue":"2","key":"4530_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00277-019-03902-9","volume":"99","author":"X Zhang","year":"2020","unstructured":"Zhang X, Li J, Jin J, Yu W (2020) Relapsed\/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen. Ann Hematol 99(2):395\u2013397","journal-title":"Ann Hematol"},{"issue":"1","key":"4530_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Keith P, Vinod P et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7\u201317","journal-title":"Blood"},{"key":"4530_CR14","doi-asserted-by":"crossref","unstructured":"Steensma DP, Baer MR, Slack JL et al Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 27:3842\u20133848","DOI":"10.1200\/JCO.2008.19.6550"},{"key":"4530_CR15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","volume":"28","author":"AF Cashen","year":"2010","unstructured":"Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF (2010) Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 28:556\u2013561","journal-title":"J Clin Oncol"},{"issue":"21","key":"4530_CR16","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","volume":"375","author":"JS Welch","year":"2016","unstructured":"Welch JS, Petti AA, Miller CA et al (2016) TP53 and Decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med 375(21):2023\u20132036","journal-title":"N Engl J Med"},{"issue":"4","key":"4530_CR17","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/bjh.14455","volume":"176","author":"C-K Chang","year":"2017","unstructured":"Chang C-K, Zhao Y-S, Xu F, Guo J, Zhang Z, He Q, Wu D, Wu L-Y, Su J-Y, Song L-X, Xiao C, Li X (2017) TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes. Br J Haematol 176(4):600\u2013608","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04530-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04530-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04530-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T03:05:12Z","timestamp":1643857512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04530-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["4530"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04530-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"assertion":[{"value":"21 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}